Results 41 to 50 of about 208,148 (266)

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Anderson, Ashley Hamilton, Bhatia, Bin Zhang, Branford, Carsten Müller-Tidow, Chen, Chomel, Chu, Copland, Corbin, Daley, Druker, Druker, Druker, Elaine K. Allan, Felsher, Franck E. Nicolini, G. Vignir Helgason, Gabert, Gorre, Gothert, Graham, Hamilton, Hayette, Holyoake, Hughes, Hurtz, Jiang, Jordan, Jordanides, Jorgensen, Konig, Konig, Konig, Koschmieder, Li, Lombardo, Lugo, Mirle Schemionek, Myssina, Notta, Pellicano, Ravi Bhatia, Samanta, Samanta, Schemionek, Scott, Shachaf, Shah, Sharma, Sharma, Sobrinho-Simoes, Steffen Koschmieder, Svetlana Myssina, Talpaz, Tessa L. Holyoake, Valerie G. Brunton, Wang, Weinstein, Weisberg, White   +61 more
core   +1 more source

Segmentation of Planning Target Volume in CT Series for Total Marrow Irradiation Using U-Net [PDF]

, 2023
Radiotherapy (RT) is a key component in the treatment of various cancers, including Acute Lymphocytic Leukemia (ALL) and Acute Myelogenous Leukemia (AML). Precise delineation of organs at risk (OARs) and target areas is essential for effective treatment planning. Intensity Modulated Radiotherapy (IMRT) techniques, such as Total Marrow Irradiation (TMI)
arxiv   +1 more source

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]

, 2016
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet, Bhatia, Ravi, Campbell, Victoria L., Chu, Su, Gaal, Karl, Holyoake, Tessa L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Zhang, Bin   +9 more
core   +1 more source

Stability Analysis of a Simplified Yet Complete Model for Chronic Myelegenous Leukemia [PDF]

Bulletin of Mathematical Biology 72, 7 (2010) 1732-1759, 2009
We analyze the asymptotic behavior of a partial differential equation (PDE) model for hematopoiesis. This PDE model is derived from the original agent-based model formulated by (Roeder et al., Nat. Med., 2006), and it describes the progression of blood cell development from the stem cell to the terminally differentiated state.
arxiv   +1 more source

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T., Brümmendorf, T. H., Chatain, N., Copland, M., Costa, I. G., Gusmao, E. G., Haenzelmann, S., Hamilton, A., Helgason, G.V., Herrmann, O., Holyoake, T. L., Kintsler, S., Koschmieder, S., Li, S., Merle Reher, M., Müller-Tidow, C., Schemionek, M., Schubert, C., Schwab, A.   +18 more
core   +1 more source

Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories.

Pakistan Journal of Biological Sciences, 2022
Background and Objective: Chronic Myelogenous Leukaemia (CML) is a clonal myeloproliferative tumor distinguished by the existence of the Philadelphia chromosome (Ph) resulting from the t (9, 22) (q34, q11) translocation.
Hala Elsir Khair, Babker Ahmed Mohamed, Bakri Yousef Nour, Hisham Ali Waggiallah   +3 more
semanticscholar   +1 more source

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? [PDF]

Reviews in Clinical Medicine, 2015
Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement.
Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati   +2 more
doaj   +3 more sources

A mathematical study of the hematopoiesis process with applications to chronic myelogenous leukemia [PDF]

SIAM Journal on Applied Mathematics 65, 4 (2005) 1328-1352, 2009
This paper is devoted to the analysis of a mathematical model of blood cells production in the bone marrow (hematopoiesis). The model is a system of two age-structured partial differential equations. Integrating these equations over the age, we obtain a system of two nonlinear differential equations with distributed time delay corresponding to the cell
arxiv   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S, Burger H, Burgess MR, Cortes J, Crossman LC, Donato NJ, Druker BJ, Gambacorti-Passerini C, Giles F, Hochhaus A, Hughes TP, Iacobucci I, Kantarjian H, Lahaye T, Mahon FX, Melo JV, O'Hare T, Quintas-Cardama A, Rousselot P, Sleijfer S, Soverini S, Weisberg E   +21 more
core   +1 more source

Chronic myelogenous leukemia presenting with Morel Lavallée lesion: A case report of a rare presentation

Clinical Case Reports, 2022
Chronic myelogenous leukemia is a myeloproliferative neoplasm characterized by the BCR‐ABL1 fusion gene and the development of the Philadelphia chromosome, which leads to an increase in granulocytes and bone marrow myeloid precursors in the blood, it can
Sara S. I. Mohamed, Hana Mahmoud Qasim, Ahmed Mahfouz, Maab A. Osman, Ashraf O. E. Ahmed, Safa H. Al‐Azewi, Mohamad A. Yassin, Shehab Fareed   +7 more
doaj   +1 more source